A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD

NCT ID: NCT01192191 Phase: PHASE3 Status: COMPLETED Enrollment: 187 Completion: 2012-01

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg, Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg

Summary

The primary purpose of the study is to evaluate the safety and tolerability of fluticasone furoate/GW642444 inhalation powder when administered once-daily for 52 weeks in Japanese patients with COPD.

Primary Outcome

Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period

Source

ClinicalTrials.gov